EVENTS · PCVX
PEERS
EARNINGS
Vaxcyte Inc. is a clinical-stage vaccine company focused on developing next-generation vaccines for bacterial infectious diseases. The company uses its proprietary cell-free protein synthesis platform to design and produce optimized protein carriers and antigens, supporting the creation of conjugate and protein-based vaccine candidates. Its current pipeline centers on pneumococcal programs aimed at preventing invasive pneumococcal disease, along with additional candidates targeting other serious bacterial conditions. Vaxcyte Inc. operates in the biotechnology and infectious disease markets, where its work addresses areas with significant unmet medical need. Based in San Carlos, California, the company is known for its emphasis on broad-spectrum vaccine design and advanced manufacturing methods that differ from conventional cell-based approaches.
| Series | 1W | 1M |
|---|---|---|
| PCVX | +6.9% | −1.5% |
| Peers | +1.7% | +5.5% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 64 | 21 |
Vaxcyte Reports Positive OPUS-1 Phase 3 Topline Data for VAX-31 in Third Quarter 2026
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q2 FY2026 | −2.10 | −1.97 | +6.04% | +2.25% |
| Q1 FY2026 | −1.79 | −2.30 | −28.74% | −7.48% |
| Q4 FY2025 | −1.55 | −1.80 | −16.44% | +4.61% |
| Q3 FY2025 | −1.29 | −1.56 | −20.53% | −5.86% |
| Series | 1W | 1M |
|---|---|---|
| PCVX | +6.9% | −1.5% |
| Peers | +1.7% | +5.5% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 64 | 21 |
